Outlook Therapeutics (OTLK) Fundamental Analysis: Revenue, Earnings & Valuation

8.57 / 10

Outperform

Fundamental analysis scores 8.6/10. Highlights include excellent interest coverage (35.1), strong revenue‑to‑market‑value (-0.11) and asset‑to‑market‑value (-0.55) differentials, and solid PB‑ROE (1.76). Weaknesses are high current liabilities ratio (90%) and elevated long‑term debt to working capital (6.38), which drag the profile.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score3/3

Weight36.04%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.50%

1M Return0.13%

Inventory turnover ratio

Value0.81

Score2/3

Weight-4.11%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value90.24

Score1/3

Weight-5.75%

1M Return-1.69%

PB-ROE

Value1.76

Score2/3

Weight33.62%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value6.39

Score0/3

Weight-15.66%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.18%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.20%

1M Return0.05%

Cost of sales ratio (%)

Value95.95

Score2/3

Weight-3.95%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight63.28%

1M Return11.61%

Is OTLK fundamentally strong?

OTLK scores 8.57/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -0.21 P/E ratio, -0.57 P/B ratio, and -16.53% earnings growth, these metrics solidify its Outperform investment rating.